MAP
UTHR icon

Moody Aldrich Partners’s United Therapeutics UTHR Stock Holding History

Moody Aldrich Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,475
Closed -$798K – 242
2024
Q1 		$798K Buy
3,475
+1,451
+72% +$327K 0.14% 124
2023
Q4 		$445K Hold
2,024
– – 0.08% 140
2023
Q3 		$457K Buy
+2,024
New +$466K 0.09% 131

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moody Aldrich Partners's UTHR Position: Q2 2024 in Review

Moody Aldrich Partners sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 3,475 shares — an estimated $798K sold.

Moody Aldrich Partners first reported a position in UTHR in Q3 2023 and held it in 3 quarters. The position peaked at $798K in Q1 2024. 568 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Moody Aldrich Partners reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 3,475 United Therapeutics shares in Q2 2024, an estimated $798K.
  • Moody Aldrich Partners first reported a position in United Therapeutics in Q3 2023 and held it in 3 quarters.
  • Moody Aldrich Partners's United Therapeutics position peaked at $798K in Q1 2024.
  • 568 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.